亞洲 蛋白降解劑
蛋白降解：不只抑制致病蛋白，而是直接把它拆掉。
7追蹤資產
0已核准
這個賽道在做什麼
PROTAC 與分子膠會把致病蛋白拉到細胞內負責回收的 E3 連接酶旁邊，讓細胞自己把它分解掉。這讓過去「沒有口袋可以下藥」的蛋白也有機會成為藥物標靶。雄性素受體、BTK 等降解劑已進入後期臨床，AI 設計與新的 E3 連接酶是競爭重點。
階段分布
第二期3 3
第一／二期1 1
第一期3 3
國家分布
中國7 7
資產表
| 排名 | 資產 | 國際非專利名稱 | 原研公司 | 國家 | 標的 | 機轉 | 最高階段 | 適應症 | 試驗登錄號 | 海外權利人 | 交易日期 | 首付款 | 總額上限 | 最新事件 | 最新事件日期 | 來源 | 來源日期 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GT20029 | — | Kintor Pharmaceutical Limited (Suzhou Kintor) | China | Androgen receptor (AR) | Topical AR-targeting PROTAC degrader | Phase 2 — China (2023-04) | Androgenetic alopecia; acne vulgaris | NCT06692465 | None reported | — | — | — | China acne Phase 2 met its primary endpoint, company announcement | 2025-08-12 | 1 2 3 4 | 2025-08-12 |
| 2 | HP518 | — | Hinova Pharmaceuticals Inc. | China | Androgen receptor (AR) | Oral AR-targeting PROTAC degrader | Phase 2 — China (2024-12) | Metastatic castration-resistant prostate cancer | NCT06155084 | None reported | — | — | — | Hinova interim disclosure describes China Phase 2 development and combination IND progress | 2026-08-27 | 1 2 3 | 2026-08-27 |
| 3 | HRS-1358 | — | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | China | Estrogen receptor (ER) | Oral ER-targeting PROTAC degrader | Phase 2 — China (confirmed 2025-05; combination) | Advanced breast cancer, combination therapy | NCT06555068 | NCT06679036 | None reported | — | — | — | Combination-study registry updated; recruiting | 2026-10-22 | 1 2 3 4 5 | 2026-10-22 |
| 4 | ICP-490 | — | InnoCare Pharma / Beijing InnoCare Pharma Tech Co., Ltd. | China | IKZF1 (Ikaros); IKZF3 (Aiolos) | CRBN-recruiting molecular glue degrader | Phase 1/2 — China (2023-03; registry status unknown) | Relapsed/refractory multiple myeloma; non-Hodgkin lymphoma | NCT05719701 | NCT06845241 | None reported | — | — | — | NHL Phase 1/2 registered; not yet recruiting | 2025-02-25 | 1 2 3 4 | 2025-02-25 |
| 5 | HSK29116 | — | Haisco Pharmaceutical Group Co., Ltd. | China | Bruton tyrosine kinase (BTK) | BTK-targeting PROTAC degrader | Phase 1 — China / Australia (2021-08; registry status unknown) | Relapsed/refractory B-cell malignancies | NCT04861779 | None reported | — | — | — | Company investor Q&A confirms earlier PROTAC programs remain in early clinical development | 2025-04-25 | 1 2 3 4 | 2025-04-25 |
| 6 | HSK40118 | — | Haisco Pharmaceutical Group Co., Ltd. | China | Mutant epidermal growth factor receptor (EGFR) | EGFR-targeting PROTAC degrader | Phase 1 — China (2023-03; registry last updated 2023-09) | EGFR-mutant advanced non-small cell lung cancer | NCT06050980 | None reported | — | — | — | Company investor Q&A confirms earlier PROTAC programs remain in early clinical development | 2025-04-25 | 1 2 3 4 | 2025-04-25 |
| 7 | ICP-538 | — | InnoCare Pharma / Beijing InnoCare Pharma Tech Co., Ltd. | China | VAV1 | Oral CRBN-recruiting VAV1 molecular glue degrader | Phase 1 — China (2026-03) | Autoimmune disease development; healthy-volunteer first-in-human trial | NCT07535099 | None reported | — | — | — | Phase 1 registry updated; recruiting | 2026-06-18 | 1 2 3 | 2026-06-18 |